Fresenius Medical Care Advances Precision Nephrology Through Hemodiafiltration and Artificial Intelligence Research

Fresenius Medical Care Advances Precision Nephrology Through Hemodiafiltration and Artificial Intelligence Research

(IN BRIEF) Fresenius Medical Care will present multiple studies at ASN Kidney Week 2025, highlighting how hemodiafiltration (HDF) enhances clinical outcomes and how artificial intelligence is transforming kidney care. One of the featured oral presentations links HDF to a reduced risk of cardiovascular and fluid-related hospitalizations, while additional abstracts explore AI-driven innovations such as fall risk prediction and clinician support chatbots. The company will also host and participate in key symposia focused on evidence-based kidney therapy and AI adoption. With these contributions, Fresenius Medical Care reaffirms its leadership in combining technology and medical expertise to advance precision nephrology and improve patient outcomes. 

(PRESS RELEASE) BAD HOMBURG, 30-Oct-2025 — /EuropaWire/ — Fresenius Medical Care will showcase groundbreaking research on hemodiafiltration (HDF) and artificial intelligence (AI) during the upcoming American Society of Nephrology (ASN) Kidney Week 2025, held from November 5–9 in Houston. The company’s latest studies provide compelling real-world evidence of the benefits of HDF for patients with kidney disease and demonstrate how AI-driven technologies are being integrated into clinical practice to improve care outcomes.

The research underscores Fresenius Medical Care’s commitment to advancing patient-centered innovation through both advanced therapies and digital health solutions. “These findings reflect our mission to enhance the quality of life for patients by combining science, technology, and clinical excellence,” said Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care. “By optimizing hemodiafiltration and harnessing AI, we’re redefining how kidney replacement therapy can deliver personalized and transformative care worldwide.”

The company’s Global Medical Office will present several scientific abstracts spanning innovations in therapy, clinical management, and digital support. One of the featured oral presentations, “Hemodiafiltration is associated with reduced risk of cardiovascular and fluid-related hospitalization outcomes,” explores how HDF may help lower the likelihood of hospitalizations caused by cardiovascular complications and fluid overload.

Additional presentations at ASN Kidney Week 2025 will include:

Implementation of Online High-Volume Hemodiafiltration in a Chronic Hemodialysis Center in the U.S., describing the first U.S. chronic dialysis facility to integrate high-volume HDF.

Preventing Falls in Patients on Dialysis Through AI-Driven Risk Prediction, which introduces a predictive model capable of forecasting patient fall risk within 31 days.

Supporting Clinician Adoption of Hemodiafiltration: A Real-Time AI Chatbot with Verified Clinical Sources, presenting a new digital tool that provides real-time education and guidance for clinicians adopting HDF.

From Prompt to Plate: Can ChatGPT Plan a Safe and Clinically Appropriate Diet for Hemodialysis Patients?, assessing the reliability of generative AI models in formulating safe, nutritionally appropriate meal plans for patients undergoing dialysis.

Dr. Maddux added, “We are proud to see how our research initiatives are influencing day-to-day clinical practice. By bridging data-driven insights with AI innovation, Fresenius Medical Care continues to set new benchmarks for the future of nephrology.”

Beyond the scientific sessions, Fresenius Medical Care will take part in several special events during ASN Kidney Week:

A breakfast symposium titled “HighVolumeHDF: The Next Standard of Care for U.S. Patients – Evidence and Practical Use” (Thursday, November 6) as part of the ASN Exhibitor Spotlight series.

An educational symposium organized by ASN, “Hemodiafiltration: Considerations for Incorporation into Dialysis Care,” supported by an educational grant from Fresenius Medical Care (Friday, November 7).

The Renal Research Institute (RRI), a Fresenius subsidiary, will host its annual symposium “Reimagining Frontline Care: The Power of Research, AI, and Innovation” (Tuesday, November 4), focusing on practical applications of AI and digital health tools in nephrology.

Fresenius Medical Care experts and researchers will be available for discussions at Booth #1815, while representatives from RRI will be present at Booth #1838 to share insights into their latest findings and collaborations.

Further details about Fresenius Medical Care’s ASN 2025 participation can be found at freseniusmedicalcare.com/en-us/asn-2025/.

About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,676 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 300,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact:

Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com

Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

Contact for analysts and investors:

Dr. Dominik Heger
T +49 6172 609 2525
Dominik.Heger@FreseniusMedicalCare.com
www.freseniusmedicalcare.com 

SOURCE: Fresenius Medical Care AG